UNASSIGNED: @entity1074 ( @entity1074 ) is a heterogeneous B-cell malignancy for which no standard treatment exists. @entity1074 is frequently linked to @entity281 , which may induce B-cell receptor (BCR) signaling resulting in aberrant B-cell survival and proliferation. We conducted a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of @entity6490 in previously treated @entity1074 . @entity1 with histologically-confirmed @entity1074 of all subtypes who received >= 1 prior therapy with an anti- @entity2225 antibody-containing regimen were treated with @entity6490 560 mg orally once daily until progression or unacceptable @entity137 . The primary end point was independent review committee-assessed overall response rate (ORR) by 2007 IWG criteria. Among 63 enrolled @entity1 , median age was 66 years (range, 30-92). Median number of prior systemic therapies was 2 (range, 1-9), and 63% received >= 1 prior chemoimmunotherapy. In 60 evaluable @entity1 , ORR was 48% (95% CI, 35-62). With median follow-up of 19.4 months, median duration of response was not reached (95% CI, 16.7-NE), and median progression-free survival was 14.2 months (95% CI, 8.3-NE). Grade >= 3 adverse events (AEs; >5%) included @entity417 , @entity55 , and @entity1295 . Serious AEs of any grade occurred in 44%, with grade 3-4 @entity55 being the most common (8%). Rates of discontinuation and dose reductions due to AEs were 17% and 10%, respectively. Single-agent @entity6490 induced durable responses with a favorable benefit-risk profile in @entity1 with previously treated @entity1074 , confirming the role of BCR signaling in this malignancy. Given the lack of approved therapies, @entity6490 may provide a treatment option without chemotherapy for @entity1074 .

Targeting BTK with XXXX in relapsed/refractory marginal zone lymphoma.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity1074 :: ('MESH:D018442', 'Disease') :: ['MZL', 'Marginal zone lymphoma'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity281 :: ('MESH:D007239', 'Disease') :: ['chronic infection'] @entity6490 :: ('MESH:C551803', 'Chemical') :: ['ibrutinib']
@entity6490 :: (MESH:C551803,Chemical) :: ['ibrutinib']
